Temacrazine
Alternative Names: NSC 687025Latest Information Update: 02 Dec 2003
At a glance
- Originator National Cancer Institute (USA); Nonindustrial sources
- Developer National Cancer Institute (USA)
- Class Acridines; Antineoplastics; Antivirals; Piperazines
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 02 Dec 2003 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
- 24 Jun 2001 No-Development-Reported for HIV-1 infections in USA (Unknown route)
- 24 Apr 1998 Preclinical development for HIV-1 infections in USA (Unknown route)